Neoadjuvant chemotherapy (NAC) has been increasingly used in breast cancer patients for tumor downstaging and more breast conservation feasibility as well as to provide a window for preoperative tumor shrink, thus guiding adjuvant systemic therapy, especially for HER2+ and TNBC patients.4 The gene discussed is ERBB2; the disease is breast carcinoma.